Evidence map›Paper›PMID 35044592›Full record

ArticleAnnals of nuclear medicine2022

Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223.

Matteo Bauckneht, Rita Lai, Francesca D'Amico, Alberto Miceli, Maria Isabella Donegani, Cristina Campi, Daniela Schenone, Stefano Raffa, Silvia Chiola, Francesco Lanfranchi and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Annals of nuclear medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. From pixels to predictions: the scrying power of molecular imaging.European journal of nuclear medicine and molecular imaging · 2024
    Article
  5. Article
  6. Observational
  7. Article
  8. Beyond the Prognostic Value of 2-[Diagnostics (Basel, Switzerland) · 2022
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Matteo BaucknehtDepartment of Health Sciences (DISSAL), University of Genova, Genova, Italy. matteo.bauckneht@gmail.com.ORCID http://orcid.org/0000-0002-1937-9116
Rita LaiDepartment of Mathematics (DIMA), University of Genoa, Genoa, Italy.
Francesca D'AmicoDepartment of Health Sciences (DISSAL), University of Genova, Genova, Italy.
Alberto MiceliDepartment of Health Sciences (DISSAL), University of Genova, Genova, Italy.
Maria Isabella DoneganiDepartment of Health Sciences (DISSAL), University of Genova, Genova, Italy.
Cristina CampiLISCOMP, Department of Mathematics (DIMA), University of Genoa, Genoa, Italy.
Daniela SchenoneLISCOMP, Department of Mathematics (DIMA), University of Genoa, Genoa, Italy.
Stefano RaffaDepartment of Health Sciences (DISSAL), University of Genova, Genova, Italy.
Silvia ChiolaNuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Francesco LanfranchiDepartment of Health Sciences (DISSAL), University of Genova, Genova, Italy.
Sara Elena RebuzziMedical Oncology, Ospedale San Paolo, Savona, Italy.
Elisa ZanardiAcademic Unit of Medical Oncology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Malvina CremanteMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Cecilia MariniNuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Giuseppe FornariniMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Silvia MorbelliDepartment of Health Sciences (DISSAL), University of Genova, Genova, Italy.
Michele PianaLISCOMP, Department of Mathematics (DIMA), University of Genoa, Genoa, Italy.
Gianmario SambucetiDepartment of Health Sciences (DISSAL), University of Genova, Genova, Italy.
University of Genoa · ITOspedale Policlinico San Martino · ITInstitute of Molecular Bioimaging and Physiology · ITOspedale San Paolo · ITSuperconducting and other Innovative Materials and Devices Institute · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAndrogen deprivation therapy alters body composition promoting a significant loss in skeletal muscle (SM) mass through inflammation and oxidative damage. We verified whether SM anthropometric composition and metabolism are associated with unfavourable overall survival (OS) in a retrospective cohort of metastatic castration-resistant prostate cancer (mCRPC) patients submitted to 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) imaging before receiving Radium-223. PATIENTS AND

methodsLow-dose CT were opportunistically analysed using a cross-sectional approach to calculate SM and adipose tissue areas at the third lumbar vertebra level. Moreover, a 3D computational method was used to extract psoas muscles to evaluate their volume, Hounsfield Units (HU) and FDG retention estimated by the standardized uptake value (SUV). Baseline established clinical, lab and imaging prognosticators were also recorded.

resultsSM area predicted OS at univariate analysis. However, this capability was not additive to the power of mean HU and maximum SUV of psoas muscles volume. These factors were thus combined in the Attenuation Metabolic Index (AMI) whose power was tested in a novel uni- and multivariable model. While Prostate-Specific Antigen (PSA), Alkaline Phosphatase (ALP), Lactate Dehydrogenase and Hemoglobin, Metabolic Tumor Volume, Total Lesion Glycolysis and AMI were associated with long-term OS at the univariate analyses, only PSA, ALP and AMI resulted in independent prognosticator at the multivariate analysis.

conclusionThe present data suggest that assessing individual 'patients' SM metrics through an opportunistic operator-independent computational analysis of FDG PET/CT imaging provides prognostic insights in mCRPC patients candidates to receive Radium-223.

Indexed as

Prostatic Neoplasms, Castration-ResistantRadiumAndrogen AntagonistsFluorodeoxyglucose F18HumansMaleMuscle, SkeletalPositron Emission Tomography Computed TomographyPrognosisRetrospective StudiesAndrogen AntagonistsFluorodeoxyglucose F18RadiumRadium-22318F-FluorodeoxyglucoseMetastatic castration-resistant prostate cancerPositron emission tomographyRadium-223SarcopeniaSkeletal muscle

Identifiers

PMID35044592
PMCPMC8938339
OpenAlexW4206844028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.